San Jose, CA, United States of America

Ben J Verwer


Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 45(Granted Patents)


Company Filing History:


Years Active: 1997

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ben J Verwer: Innovator in Acute Leukemia Diagnostics

Introduction

Ben J Verwer, an inventive mind based in San Jose, CA, has made significant strides in the field of medical diagnostics. His patent, focused on the automatic lineage assignment of acute leukemias through flow cytometry, reflects groundbreaking innovation aimed at improving the efficiency and accuracy of leukemia diagnosis.

Latest Patents

Ben J Verwer holds a patent titled "Automatic lineage assignment of acute leukemias by flow cytometry." This method involves an advanced approach where eight four-parameter list mode data files are systematically acquired with a flow cytometer. The sequence includes various stages such as unstained samples, isotype controls, and different combinations of fluorescent markers. By utilizing a nearest neighbors clustering algorithm, the data files are analyzed to identify distinct cell populations, which aids in classifying leukemic cell populations while eliminating normal cell populations from consideration.

Career Highlights

Ben is associated with Becton Dickinson and Company Limited, where he contributes to pioneering advancements in medical technology. His work is instrumental in developing methodologies that streamline the diagnostic process for acute leukemias, thereby enhancing patient outcomes and facilitating timely treatment interventions.

Collaborations

He collaborates closely with fellow innovator Leon W Terstappen. Their combined efforts and expertise foster a creative environment leading to significant advancements in hematological diagnostics.

Conclusion

Through his patent and collaborative efforts, Ben J Verwer demonstrates a commitment to advancing medical diagnostics. His innovative approach is set to impact the field significantly, providing clinicians with tools that enable more efficient and precise detection of acute leukemias, ultimately benefiting patient care and treatment strategies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…